Company news
Valerio Therapeutics news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic
October 11, 2026
Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026
October 6, 2026
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
August 24, 2026
Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition
August 17, 2026
Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update
July 16, 2026
Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines
July 1, 2026
Valerio Therapeutics announces binding offer for the proposed acquisition of Etherna Immunotherapies, creating a global leader in targeted RNA medicines
July 1, 2026
Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
June 16, 2026
Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
June 16, 2026
Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company
May 18, 2026
Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches
May 4, 2026
Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model
April 29, 2026
Valerio Therapeutics publishes its 2025 annual results and annual financial report, and confirms the strategic transformation of its operating model
April 28, 2026
Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors
December 17, 2025
Valerio Therapeutics announces the appointment of Eric Vivier as observer to its Board of Directors
December 15, 2025
Completion of the merger between Valerio Therapeutics and its subsidiary valour bio
December 12, 2025
Valerio Therapeutics announces changes in the composition of its Board of Directors
November 26, 2025
Cooptation d'Antonin de Fougerolles en qualité d' Administrateur de Valerio Therapeutics
November 26, 2025
Projet de fusion entre Valerio Therapeutics et sa filiale Valour Bio
October 31, 2025
Projet de fusion entre Valerio Therapeutics et sa filiale valour bio
October 31, 2025
Valerio Therapeutics: Proposed merger between Valerio Therapeutics and its subsidiary Valour Bio
October 31, 2025
Press Release Publication Half-Year Financial Report 2025
October 30, 2025
Half-Year Financial Report 2025
October 30, 2025
2025 Half-Yearly Financial Report
October 29, 2025
Valerio Therapeutics réalisation d'une augmentation de capital avec surpression du droit préférentiel de souscription
October 16, 2025
Valerio Therapeutics announces the completion of a capital increase with cancellation of preferential subscription rights
October 15, 2025
Transactions on the share capital of Valerio Therapeutics to restructure part of its liabilities
July 22, 2025
Valerio Therapeutics: Postponement of 2024 Annual Financial Report Publication and the Approval of Financial Statements
May 6, 2025
Decks
- Investor Presentation (July 2026)
Investor deck · 18 slides · July 2026
- Investor Presentation (October 2025)
Investor deck · 13 slides · October 2025
- Investor Presentation (May 2025)
Investor deck · 11 slides · May 2025